HK-listed Luye Pharma may secure up to $220m from China's state-owned fund manager

State-owned Shenzhen Investment Holdings Capital has agreed to invest up to 1.6 billion yuan ($220 million) into a wholly-owned subsidiary of Hong Kong-listed Luye Pharma Group as part of the latter’s plan to boost its oncology drug business.